13/02/2018 15:30:00

Medovex Corporation Presents Initial Data on the DenerveX® System During NSpine 2nd Platinum Course in Arosa, Switzerland

ATLANTA, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Medovex Corp. (OTCQB:MDVX) ("Medovex" or the "Company"), the developer of the DenerveX® System, a new and novel device designed for enduring relief of Facet Joint Syndrome related to chronic back pain, a non-addictive, non-opioid drug alternative capable of restoring a patient to a more normal and active lifestyle, today announced that the Company participated at the NSpine Platinum Small Group Educational Event in Arosa, Switzerland, held January 29th through February 3rd, 2018.

Medovex medical advisory board member Vik Kapoor MD, from Manchester, U.K. presented on two separate days at the N-Spine Platinum Small Group Educational Event. Dr. Kapoor presented initial data on his first 20 cases using the DenerveX System, which he considers very positive. The presentation was well received by approximately 50 European neuro, spinal, and orthopedic surgeons. Attending surgeons were granted 30 European CME credits (6 ECMEC® per day) by the European Accreditation Council for Continuing Medical Education (EACCME). 

A third day marketing presentation focused on the DenerveX System including discussion related to reimbursement opportunities specific to individual countries, leading to expressed interest from many attendees to start performing DenerveX cases in their respective countries.

In an effort to enhance the value of the meeting, the third day of the event consisted of novel technologies identified by NSpine as improving the field of spine care. The Medovex team was pleased to have been selected.

The value of the Arosa meeting lies in its educational content – to gain a greater understanding of current trends and decision making in spinal surgery – and in the networking with senior decision makers in the world of spinal surgery.

Manfred Sablowski, Medovex Senior Vice President of Global Sales & Marketing stated, “We are pleased to have been selected for participation at The NSpine Platinum Small Group Educational Event. The professional networks built through these events are as valuable as the educational content itself. During this master’s course, Medovex had the privilege of meeting many of the world’s preeminent surgeons who we continue to draw on for advice in managing unusually complex cases.”

Sablowski continued, “Events like these are important milestones for Medovex, as well as a key inflection point gaining us leverage for our Company’s growth strategy focused in Europe, South America, and Australia. Importantly, it provides potential future customers the opportunity to experience firsthand the intuitive DenerveX System.”

Please also follow us on Facebook at https://www.facebook.com/medovex/.

About Medovex

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX System, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com.

Safe Harbor Statement                                                     

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact Information

 

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Aug
PNDORA
Foerst den ene vej 📈 og saa den anden vej 📉 og tju og tju og skomagerdreng... 🎶 Jeg er helt overb..
29
14 Aug
VELO
Vi har diskuteret markedet for immunosuppressive medikamenter før, og jeg har i et tidligere indlæg ..
23
16 Aug
GEN
Det er interimdata vi venter på og altså ikke det fulde data sæt - kigger vi på de tre andre fase II..
19
17 Aug
VELO
Q2-18 er udkommet og jeg har fået set lidt på regnskabet. Overordnet set fulgte selskabets resultat ..
18
15 Aug
VELO
Bare t.o. Jeg taler efter planen med Craig Collard i eftermiddag og sender en artikel ud i morgen.  ..
18
13 Aug
VELO
Husk at markedet er gigantisk! Astellas' to produkter AstagrafXL og Prograf solgte for ca. 12 mia. k..
18
15 Aug
 
Endnu et fantast firma på First North...og denne gang med det flatterende navn Hypefactor...   Når m..
16
13 Aug
VELO
Dette er på alle måder et super regnskab. jeg er helt enig med dem der forventer endnu en opjusterin..
16
13 Aug
PNDORA
22,8 mia. kr. i 2017 synes smykkerne var pæne. det tæller mere end din ene mening
16
14 Aug
VELO
Svar fra Kevin Grønnemann, Medwatch.....   Mange tak for din mail og for jeres forslag.   Det er nog..
14

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Sophos Sweeps Network and Endpoint Security Categories in CRN’s 2018 Annual Report Card – Again!
2
SHAREHOLDER ALERT: FIZZ ACAD FB ABBV TTPH RMTI HMNY GDS NLSN ZN SBGI ORCL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
3
SHAREHOLDER ALERT: MRCY GLCNF GLNCY MD COOL HAIR FPI SBGL NWL GOGO FLKS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
4
Key Energy Services Announces Appointment of Rob Saltiel as New President and Chief Executive Officer
5
AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzheimer's Disease and Down Syndrome

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 August 2018 13:32:11
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180816.1 - EUROWEB2 - 2018-08-20 14:32:11 - 2018-08-20 13:32:11 - 1000 - Website: OKAY